UNC93B1: A Non-Coding RNA Molecule with Potential Drug Targeting and Biomarker Properties

Target Name: UNC93B1

NCBI ID: G81622

UNC93B1

UNC93B1: A Non-Coding RNA Molecule with Potential Drug Targeting and Biomarker Properties

UNC93B1, also known as unc-93 homolog B1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and location in the gene universe make it an intriguing candidate for research into various diseases.

UNC93B1 is a member of the UNC93 family of non-coding RNAs, which are known for their ability to interact with protein-coding genes to regulate gene expression. The B1 subunit of UNC93B1 is a smaller isoform that has been shown to interact with several protein-coding genes, including the transcription factor ASXL1.

ASXL1 is a key regulator of stem cell proliferation and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. ASXL1 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. This process is important for the growth and development of tissues and is also involved in the treatment of certain diseases.

Research has suggested that UNC93B1 may be a drug target for diseases that are characterized by the over-expression of ASXL1. This is because UNC93B1 has been shown to interact with ASXL1 and may regulate its activity. Additionally, studies have shown that UNC93B1 is highly expressed in various tissues and organs, including brain, heart, and liver, which suggests that it may be involved in a variety of physiological processes.

Another potential mechanism by which UNC93B1 may be involved in disease is its role in the regulation of cellular processes that are critical for the development and maintenance of tissues. For example, UNC93B1 has been shown to play a role in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. This process is important for the development and maintenance of tissues and is also involved in the treatment of certain diseases, such as cancer.

In addition to its potential role in drug targeting and tissue regulation, UNC93B1 has also been shown to be a potential biomarker for a variety of diseases. This is because its expression has been associated with the development and progression of several diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that UNC93B1 is highly expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disease.

Overall, UNC93B1 is a fascinating candidate for drug targeting and biomarker research due to its unique structure and location in the gene universe. Its interaction with the transcription factor ASXL1 and its potential role in the regulation of cellular processes that are critical for tissue development and maintenance make it an intriguing candidate for research into a variety of diseases. Further studies are needed to fully understand its potential and to determine its utility as a drug target and biomarker.

Protein Name: Unc-93 Homolog B1, TLR Signaling Regulator

Functions: Plays an important role in innate and adaptive immunity by regulating nucleotide-sensing Toll-like receptor (TLR) signaling. Required for the transport of a subset of TLRs (including TLR3, TLR7 and TLR9) from the endoplasmic reticulum to endolysosomes where they can engage pathogen nucleotides and activate signaling cascades. May play a role in autoreactive B-cells removal

The "UNC93B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UNC93B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets